NLS Pharma News

Pharma Business – October 29, 2026

FDA to review Orexo’s nasal naloxone powder

The US Food and Drug Administration (FDA) has accepted Uppsala-based Orexo’s resubmitted New Drug Application for IZIPRY, a high-dose naloxone nasal powder for opioid overdose. A decision is expected by March 29, 2027.

Accelerating Agentic ERP transformation at Bavarian Nordic

In this webinar, Cegeka and Mavim share how Bavarian Nordic builds process clarity for Dynamics 365, and why process visibility is key to life sciences ERP modernization and Agentic ERP.

Agreement – October 27, 2026

Thor Medical to supply alpha isotopes to UK drug discovery center

Oslo-based Thor Medical has signed a three-year agreement to supply radium-224 and lead-212 to Medicines Discovery Catapult (MDC), a UK life science service for drug discovery. The isotopes will support MDC’s work to speed up the development of radiopharmaceutical cancer therapies in the UK.

Unique Design for Lab Life – LABOPORT® Vacuum Pumps

Modular and expandable The laboratory vacuum pump system guarantees maximum performance and safety, tailored to your individual needs. The powerful basic pump can be easily modified into a higher environmentally friendly system. Various system components such as a separator, high‑performance condenser and remote vacuum controller, the system supports a wide range of laboratory applications.

Pharma Business – October 22, 2026

Orion raises 2026 outlook on royalty growth

Finnish pharmaceutical company Orion has upgraded its full-year 2026 outlook for both net sales and operating profit, as royalty income has grown faster than expected so far this year.

Clinical Trials

Clinical Trials – October 29, 2026

Sobi’s gout drug sustains uric acid reduction

Sobi’s pozdeutinurad significantly lowered serum uric acid levels in patients with uncontrolled gout, with the effect sustained for a full year, according to new Phase III data from the pivotal REDUCE-2 study. The results will be presented in a late-breaking session at ACR Convergence 2026.

Clinical Trials – October 28, 2026

Genmab drug halves death risk in head and neck cancer

Copenhagen-based Genmab says its bispecific antibody petosemtamab, given with pembrolizumab, met both primary endpoints in the global Phase III LiGeR-HN1 trial in first-line recurrent or metastatic PD-L1-positive head and neck squamous cell carcinoma.

Clinical Trials – October 28, 2026

Vicore’s IPF trial passes futility analysis

Swedish biotech Vicore Pharma’s Phase 2b ASPIRE trial of buloxibutid in idiopathic pulmonary fibrosis (IPF) has passed a pre-planned futility analysis. The independent Data Monitoring Committee recommended that the trial continue without modification, and topline results remain on track for mid-2027.

Clinical Trials – October 27, 2026

DexTech confirms positive myeloma study results

The final clinical study report from DexTech Medical’s study of OsteoDex in treatment-resistant multiple myeloma confirms the earlier preliminary results. No serious adverse events were reported, and the disease stabilized in all patients during treatment.

Clinical Trials – October 26, 2026

TILT reports durable responses in ovarian cancer

Finnish TILT Biotherapeutics has presented Phase Ib results at ESMO 2026 showing that four of nine evaluable patients with platinum-resistant ovarian cancer responded to its candidate TILT-123 combined with immunotherapy and chemotherapy. Two of the patients achieved complete responses.

Clinical Trials – October 26, 2026

AstraZeneca’s Imfinzi plus Imdelltra extends survival in small cell lung cancer

Adding Amgen’s Imdelltra (tarlatamab) to AstraZeneca’s Imfinzi (durvalumab) as first-line maintenance treatment reduced the risk of death by 58% compared with Imfinzi alone in extensive-stage small cell lung cancer, according to results from the Phase III DeLLphi-305 trial presented at ESMO 2026.

Clinical Trials – October 26, 2026

Saniona files IND for rapid-acting antidepressant candidate

Danish biotech Saniona has submitted an Investigational New Drug (IND) application to the US FDA for SAN2465 in major depressive disorder. If the FDA clears the application, the company expects to start a Phase 1 trial before the end of 2026.

Clinical Trials – October 23, 2026

Hansa’s Idefirix enables kidney transplants in European follow-up study

Hansa Biopharma’s imlifidase (Idefirix) achieved 90% graft failure-free survival one year after transplantation in highly sensitized kidney patients in the European post-authorization PAES study. The results were presented as a late-breaking abstract at ASN Kidney Week 2026 in Denver.

Clinical Trials – October 23, 2026

Genmab’s Rina-S extends survival in Phase 3 ovarian cancer trial

Genmab’s antibody-drug conjugate rinatabart sesutecan (Rina-S) significantly improved both progression-free and overall survival compared with chemotherapy in the Phase 3 RAINFOL-02 trial in women with platinum-resistant ovarian cancer.

Clinical Trials – October 21, 2026

Gesynta completes endometriosis trial enrollment

Gesynta Pharma has completed enrollment in NOVA, its Phase II trial of the non-hormonal, non-opioid drug candidate vipoglanstat in endometriosis. The trial is fully enrolled more than three months ahead of schedule, and topline data are expected in the second quarter of 2027.

Profiles in Pharma

Profiles in Pharma – April 2, 2025

The Jalkanens: A shared thirst for knowledge

For Sirpa and Markku Jalkanen of Finland, M.D. and Ph.D., married, immunotherapy researchers, working together came as naturally as a courtship.

Profiles in Pharma – November 1, 2023

Jonina Gudmundsdottir, Coripharma

In the heart of Iceland’s life sciences industry, Jonina Gudmundsdottir, the CEO of Coripharma, is making her mark. With a deep understanding of the industry’s challenges and a relentless drive for excellence, Gudmundsdottir has steered Coripharma toward transformative success. Iceland’s life sciences industry has thrived in recent years, propelled by its unique strengths. With a […]

Profiles in Pharma – July 3, 2023

Deborah Dunsire

The CEO of Lundbeck, who announced that she will retire last week, did not initially intend to join the life science industry, but it captivated her more than 30 years ago, and the ability to transform lives still drives her to this day. For more than 100 years, Lundbeck has been at the forefront of […]

Profiles in Pharma – October 1, 2021

Malin Parkler – Passionate about science, health & leadership

Malin Parkler, CEO of Pfizer Sweden, is driven by curiosity and a passion to build knowledge and evolve the life science industry – with the ultimate goal to yield real benefits for patients. Rarely has the world been more in need of leaders. As the global community struggled with the COVID-19 pandemic last year, people […]

Profiles in Pharma – August 15, 2019

Katarina Ageborg, CEO AstraZeneca Sweden

Few companies are as synonymous with Sweden as AstraZeneca and few CEOs as visible. Yet, Katarina Ageborg, AstraZeneca Sweden’s new CEO, prefers not to think about being center stage, but instead about what her position can do for the company, Sweden and the pharmaceutical industry as a whole. “I don’t think about it that way […]

Profiles in Pharma – July 1, 2017

Embracing diversity – for the sake of true innovation

Bahija Jallal’s curiosity and passion for science have been strong driving forces throughout her entire career, as has her belief in the need for diversity to truly bring forth innovation. A view that is also deeply incorporated in her job as Head of MedImmune. Editor’s note: In 2019 Bahika Jallal left MedImmune and became the […]

Profiles in Pharma – March 22, 2017

“The scientist in me wants to make a difference”

After ten years of diabetes research and development at Novo Nordisk, Dorte X. Gram took her findings and work further to start something on her own. As founder and CEO of PILA PHARMA she hopes to bring a new oral anti-diabetic agent to the market.

Profiles in Pharma – March 8, 2017

“We have to embrace the new era of diabetes care”

Mads Krogsgaard Thomsen, Executive Vice President and Chief Science Officer at Novo Nordisk, talks about the Danish pharma giant’s drug-development strategy, the new era of diabetes care and his 25 year-long passion for his job. The changing diabetes market, with increasing competition and high prices for diabetes products in the US, has made the world’s […]

Profiles in Pharma – February 16, 2017

From regulator to pharma industry specialist

Dr. Thomas Lönngren, former head of the EMA and today a pharmaceutical consultant, provides some insights on the aftermath of Brexit, describes current challenges the industry is facing and takes a short walk down memory lane on his career journey. The summer of 2016 will be remembered for many things; record temperatures, terrorist acts in […]

Profiles in Pharma – April 21, 2014

Jan Lundberg: The long view of R&D at Eli Lilly

Like sports, R&D requires team spirit, commitment, and a long view says Dr. Jan Lundberg, Lilly executive vice president for science and technology, and president of Lilly Research Laboratories. Dr. Jan Lundberg’s online bios and YouTube videos portray a steely pharmaceutical executive whose idea of fun is a 90 km ski race. It’s all true. […]

NLS Pharma News

FDA to review Orexo’s nasal naloxone powder

Accelerating Agentic ERP transformation at Bavarian Nordic

Thor Medical to supply alpha isotopes to UK drug discovery center

Unique Design for Lab Life – LABOPORT® Vacuum Pumps

Orion raises 2026 outlook on royalty growth

Sobi’s gout drug sustains uric acid reduction

Genmab drug halves death risk in head and neck cancer

Vicore’s IPF trial passes futility analysis

DexTech confirms positive myeloma study results

TILT reports durable responses in ovarian cancer

AstraZeneca’s Imfinzi plus Imdelltra extends survival in small cell lung cancer

Saniona files IND for rapid-acting antidepressant candidate

Hansa’s Idefirix enables kidney transplants in European follow-up study

Genmab’s Rina-S extends survival in Phase 3 ovarian cancer trial

Gesynta completes endometriosis trial enrollment

The Jalkanens: A shared thirst for knowledge